Dr. Ann Beliën is the Founder and CEO of Rejuvenate Biomed, a company she established in 2017. Over the past eigth years, she has transformed the organization from a discovery-phase start-up into a clinical-stage company, assembling a dynamic team of 20 experts and successfully securing international investments, from seed funding through Series B. With over 25 years of extensive experience in drug development - from bench to market - Dr. Beliën has held operational and strategic roles across oncology, neurology, immunology, and infectious diseases. Her expertise spans external and open innovation (therapeutics and prevention), alliance management, and corporate integrations and carve-outs. She has played pivotal roles in the development of several marketed compounds, including Velcade®, Dacogen®, Yondelis®,  Reminyl®, Risperdal Consta®, and Prezista® and compounds in earlier phases of development. She served on the management board of the Janssen Prevention Center and acted as their R&D due diligence lead. Dr. Beliën joined Johnson & Johnson in 2000. Prior to her tenure at J&J, she completed a postdoctoral fellowship at ETH Zurich in Switzerland. Dr. Beliën holds a PhD from the University of Zurich, Switzerland, and a master’s degree from the Free University of Brussels (VUB), Belgium.